JP2016517889A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517889A5 JP2016517889A5 JP2016512086A JP2016512086A JP2016517889A5 JP 2016517889 A5 JP2016517889 A5 JP 2016517889A5 JP 2016512086 A JP2016512086 A JP 2016512086A JP 2016512086 A JP2016512086 A JP 2016512086A JP 2016517889 A5 JP2016517889 A5 JP 2016517889A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- therapeutic
- immunosuppressant
- administration
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003018 immunosuppressive agent Substances 0.000 claims 32
- 229960003444 immunosuppressant agent Drugs 0.000 claims 30
- 230000001861 immunosuppressant effect Effects 0.000 claims 29
- 230000001225 therapeutic effect Effects 0.000 claims 27
- 238000000034 method Methods 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 16
- 239000002539 nanocarrier Substances 0.000 claims 16
- 229920002521 macromolecule Polymers 0.000 claims 15
- 230000003285 pharmacodynamic effect Effects 0.000 claims 13
- 229920000642 polymer Polymers 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000004190 Enzymes Human genes 0.000 claims 7
- 108090000790 Enzymes Proteins 0.000 claims 7
- 230000005875 antibody response Effects 0.000 claims 7
- 229940088598 enzyme Drugs 0.000 claims 7
- 239000002105 nanoparticle Substances 0.000 claims 6
- 238000007912 intraperitoneal administration Methods 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 229920000728 polyester Polymers 0.000 claims 5
- 238000007920 subcutaneous administration Methods 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 229920000570 polyether Polymers 0.000 claims 3
- 102100031491 Arylsulfatase B Human genes 0.000 claims 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 2
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 claims 2
- 108010068701 Pegloticase Proteins 0.000 claims 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 2
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 claims 2
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 claims 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000002641 enzyme replacement therapy Methods 0.000 claims 2
- 108010072166 idursulfase Proteins 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- 239000002082 metal nanoparticle Substances 0.000 claims 2
- 108010025221 plasma protein Z Proteins 0.000 claims 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 claims 1
- 108090000935 Antithrombin III Proteins 0.000 claims 1
- 102000004411 Antithrombin III Human genes 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102100022641 Coagulation factor IX Human genes 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 108010074604 Epoetin Alfa Proteins 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010014172 Factor V Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071289 Factor XIII Proteins 0.000 claims 1
- 108010074860 Factor Xa Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 108090000481 Heparin Cofactor II Proteins 0.000 claims 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 102100029199 Iduronate 2-sulfatase Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000004195 Isomerases Human genes 0.000 claims 1
- 108090000769 Isomerases Proteins 0.000 claims 1
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 108090000856 Lyases Proteins 0.000 claims 1
- 102000004317 Lyases Human genes 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 239000012826 P38 inhibitor Substances 0.000 claims 1
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 1
- 102000013566 Plasminogen Human genes 0.000 claims 1
- 108010051456 Plasminogen Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 108010066124 Protein S Proteins 0.000 claims 1
- 102000029301 Protein S Human genes 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 108010000499 Thromboplastin Proteins 0.000 claims 1
- 102000002262 Thromboplastin Human genes 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940022705 aldurazyme Drugs 0.000 claims 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960005348 antithrombin iii Drugs 0.000 claims 1
- 229920006187 aquazol Polymers 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 229940019700 blood coagulation factors Drugs 0.000 claims 1
- 229960000182 blood factors Drugs 0.000 claims 1
- -1 buckyballs Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims 1
- 229940124301 concurrent medication Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
- 229960002986 dinoprostone Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000002296 dynamic light scattering Methods 0.000 claims 1
- QBEPNUQJQWDYKU-BMGKTWPMSA-N egrifta Chemical compound C([C@H](NC(=O)C/C=C/CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(N)=O)C1=CC=C(O)C=C1 QBEPNUQJQWDYKU-BMGKTWPMSA-N 0.000 claims 1
- 229940012882 elaprase Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960003388 epoetin alfa Drugs 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 229940012426 factor x Drugs 0.000 claims 1
- 229940012444 factor xiii Drugs 0.000 claims 1
- 108010089296 galsulfase Proteins 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 108010013846 hematide Proteins 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 102000045921 human GAA Human genes 0.000 claims 1
- 229940048921 humira Drugs 0.000 claims 1
- 229960002396 idursulfase Drugs 0.000 claims 1
- 229960002127 imiglucerase Drugs 0.000 claims 1
- 108010039650 imiglucerase Proteins 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 229940120535 krystexxa Drugs 0.000 claims 1
- 229960002486 laronidase Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229940091827 lumizyme Drugs 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000004898 mitochondrial function Effects 0.000 claims 1
- 229940103023 myozyme Drugs 0.000 claims 1
- 229940068704 naglazyme Drugs 0.000 claims 1
- 239000002070 nanowire Substances 0.000 claims 1
- 229950005751 ocrelizumab Drugs 0.000 claims 1
- 229960001376 pegloticase Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001855 polyketal Polymers 0.000 claims 1
- 229920006324 polyoxymethylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000003805 procoagulant Substances 0.000 claims 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 230000009469 supplementation Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229960001874 tesamorelin Drugs 0.000 claims 1
- 108700002800 tesamorelin Proteins 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960005356 urokinase Drugs 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018231206A JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021162235A JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2024077998A JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819517P | 2013-05-03 | 2013-05-03 | |
| US61/819,517 | 2013-05-03 | ||
| US201361881851P | 2013-09-24 | 2013-09-24 | |
| US201361881913P | 2013-09-24 | 2013-09-24 | |
| US201361881921P | 2013-09-24 | 2013-09-24 | |
| US61/881,851 | 2013-09-24 | ||
| US61/881,921 | 2013-09-24 | ||
| US61/881,913 | 2013-09-24 | ||
| US201361907177P | 2013-11-21 | 2013-11-21 | |
| US61/907,177 | 2013-11-21 | ||
| US201461948313P | 2014-03-05 | 2014-03-05 | |
| US201461948384P | 2014-03-05 | 2014-03-05 | |
| US61/948,313 | 2014-03-05 | ||
| US61/948,384 | 2014-03-05 | ||
| PCT/US2014/036687 WO2014179762A1 (en) | 2013-05-03 | 2014-05-02 | Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018231206A Division JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517889A JP2016517889A (ja) | 2016-06-20 |
| JP2016517889A5 true JP2016517889A5 (enExample) | 2017-06-08 |
Family
ID=51841530
Family Applications (19)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512094A Active JP6580558B2 (ja) | 2013-05-03 | 2014-05-02 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2016512093A Active JP6818549B2 (ja) | 2013-05-03 | 2014-05-02 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2016512086A Pending JP2016517889A (ja) | 2013-05-03 | 2014-05-02 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2016512092A Active JP6760838B2 (ja) | 2013-05-03 | 2014-05-02 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2016512091A Active JP7028556B2 (ja) | 2013-05-03 | 2014-05-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2016512090A Pending JP2016520051A (ja) | 2013-05-03 | 2014-05-02 | Ｉ型およびｉｖ型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与 |
| JP2018231206A Active JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2019004287A Active JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2019155456A Pending JP2020015741A (ja) | 2013-05-03 | 2019-08-28 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2019195263A Active JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2019217946A Pending JP2020073488A (ja) | 2013-05-03 | 2019-12-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2021000191A Pending JP2021073198A (ja) | 2013-05-03 | 2021-01-04 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021162235A Active JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021193530A Pending JP2022043071A (ja) | 2013-05-03 | 2021-11-29 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2022076702A Pending JP2022122871A (ja) | 2013-05-03 | 2022-05-06 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2022076787A Active JP7440833B2 (ja) | 2013-05-03 | 2022-05-06 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2022197386A Active JP7864061B2 (ja) | 2013-05-03 | 2022-12-09 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2024077998A Pending JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2024159048A Withdrawn JP2025003994A (ja) | 2013-05-03 | 2024-09-13 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512094A Active JP6580558B2 (ja) | 2013-05-03 | 2014-05-02 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2016512093A Active JP6818549B2 (ja) | 2013-05-03 | 2014-05-02 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
Family Applications After (16)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512092A Active JP6760838B2 (ja) | 2013-05-03 | 2014-05-02 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2016512091A Active JP7028556B2 (ja) | 2013-05-03 | 2014-05-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2016512090A Pending JP2016520051A (ja) | 2013-05-03 | 2014-05-02 | Ｉ型およびｉｖ型過敏症を低減させる寛容原性の合成ナノ担体の局所的な併用投与 |
| JP2018231206A Active JP6983144B2 (ja) | 2013-05-03 | 2018-12-10 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2019004287A Active JP7134885B2 (ja) | 2013-05-03 | 2019-01-15 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2019155456A Pending JP2020015741A (ja) | 2013-05-03 | 2019-08-28 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2019195263A Active JP7427419B2 (ja) | 2013-05-03 | 2019-10-28 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2019217946A Pending JP2020073488A (ja) | 2013-05-03 | 2019-12-02 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2021000191A Pending JP2021073198A (ja) | 2013-05-03 | 2021-01-04 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021162235A Active JP7489362B2 (ja) | 2013-05-03 | 2021-09-30 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2021193530A Pending JP2022043071A (ja) | 2013-05-03 | 2021-11-29 | 望ましくない液性免疫応答を低減するための投薬の組み合わせ |
| JP2022076702A Pending JP2022122871A (ja) | 2013-05-03 | 2022-05-06 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| JP2022076787A Active JP7440833B2 (ja) | 2013-05-03 | 2022-05-06 | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 |
| JP2022197386A Active JP7864061B2 (ja) | 2013-05-03 | 2022-12-09 | Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物 |
| JP2024077998A Pending JP2024116128A (ja) | 2013-05-03 | 2024-05-13 | 薬力学的効果の低減または向上のための寛容原性合成ナノ担体および治療用高分子 |
| JP2024159048A Withdrawn JP2025003994A (ja) | 2013-05-03 | 2024-09-13 | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
Country Status (15)
| Country | Link |
|---|---|
| US (15) | US10668053B2 (enExample) |
| EP (7) | EP2991646B1 (enExample) |
| JP (19) | JP6580558B2 (enExample) |
| KR (18) | KR20160003219A (enExample) |
| CN (18) | CN105307641A (enExample) |
| AU (16) | AU2014262166B2 (enExample) |
| BR (6) | BR112015027297B1 (enExample) |
| CA (5) | CA2910575C (enExample) |
| DK (1) | DK2991646T3 (enExample) |
| EA (6) | EA201592104A3 (enExample) |
| ES (1) | ES2842206T3 (enExample) |
| HU (1) | HUE052599T2 (enExample) |
| IL (14) | IL292190A (enExample) |
| MX (12) | MX386917B (enExample) |
| WO (5) | WO2014179772A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| WO2017025889A1 (en) * | 2015-08-13 | 2017-02-16 | Pfizer Inc. | Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist |
| WO2017083659A1 (en) * | 2015-11-12 | 2017-05-18 | New York University | Biodegradable polymeric nanoparticle conjugates and use thereof |
| RS65941B1 (sr) * | 2016-03-11 | 2024-10-31 | Cartesian Therapeutics Inc | Formulacije i doze pegilovane urikaze |
| WO2017194454A1 (en) | 2016-05-09 | 2017-11-16 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
| US11365392B2 (en) * | 2016-08-05 | 2022-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof |
| JP2019530470A (ja) * | 2016-08-05 | 2019-10-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδＦｏｘｐ３＋調節性Ｔ細胞のエクスビボ生成及びその治療的使用 |
| JP2020506890A (ja) * | 2017-01-07 | 2020-03-05 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与 |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2019075360A1 (en) * | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| EP3732487A1 (en) * | 2017-12-27 | 2020-11-04 | Vito NV | Biomarkers for typing allograft recipients |
| CN108295303A (zh) * | 2018-02-08 | 2018-07-20 | 中山大学附属第三医院（中山大学肝脏病医院） | 一种钛金属植入物及其制备方法和用途 |
| CN110314236A (zh) * | 2018-03-29 | 2019-10-11 | 天津键凯科技有限公司 | 聚乙二醇与雷帕霉素的结合物及其用途 |
| CN109045304B (zh) * | 2018-04-13 | 2022-04-05 | 中山大学 | 一种携带Polymerase I抑制剂的核仁靶向纳米载体及其制备方法和应用 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| US20220252574A1 (en) * | 2019-07-22 | 2022-08-11 | University Of Louisville Research Foundation, Inc. | Immunomodulatory compositions and methods of using |
| EP4058006A4 (en) | 2019-11-11 | 2023-06-28 | The Regents Of The University Of California | Polymeric nanoparticles that target liver sinusoidal endothelial cells to induce antigen-specific immune tolerance |
| CN110747276B (zh) * | 2019-11-22 | 2020-06-30 | 山东大学齐鲁医院 | Bace2作为胶质瘤预后/诊断/治疗标志物的应用 |
| MX2022010568A (es) * | 2020-02-26 | 2022-11-30 | Selecta Biosciences Inc | Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. |
| KR20230002613A (ko) * | 2020-04-14 | 2023-01-05 | 셀렉타 바이오사이언시즈, 인크. | 자가포식을 유도하기 위한 방법 및 조성물 |
| CN113825832B (zh) * | 2020-07-28 | 2024-12-13 | 浙江大学 | 一种体外诱导CD4+Foxp3+CD69+Treg的扩增方法及其用途 |
| JP7544541B2 (ja) | 2020-09-14 | 2024-09-03 | 聡 安斎 | 地盤掘削装置 |
| CN112480244A (zh) * | 2020-11-24 | 2021-03-12 | 华科同济干细胞基因工程有限公司 | 一种抗过敏性纳米抗体组合物、抗体测定方法及喷雾剂 |
| CN112961831B (zh) * | 2021-02-26 | 2022-10-11 | 仲恺农业工程学院 | 一种肠源外泌体的制备方法 |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| BR112023021962A2 (pt) * | 2021-04-22 | 2023-12-26 | Perseo Pharma Ag | Composições biocatalíticas funcionalizadas |
| WO2023086615A1 (en) * | 2021-11-14 | 2023-05-19 | Selecta Biosciences, Inc. | Multiple dosing with viral vectors |
| EP4634233A2 (en) * | 2022-12-13 | 2025-10-22 | Dana-Farber Cancer Institute, Inc. | Checkpoint modulators for enhancing immunotherapy |
| JPWO2024181580A1 (enExample) | 2023-03-02 | 2024-09-06 | ||
| WO2024190532A1 (ja) | 2023-03-14 | 2024-09-19 | 株式会社フジミインコーポレーテッド | 研磨用組成物、研磨用組成物の濃縮液および研磨方法 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| GB202415232D0 (en) * | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
| CN121014614B (zh) * | 2025-11-03 | 2026-02-24 | 昆明医科大学 | 一种淋巴细胞保存液、制备方法及在样本预处理中的应用 |
Family Cites Families (294)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| WO1988006451A1 (en) | 1987-02-24 | 1988-09-07 | Xoma Corporation | Immunosuppression in immunotoxin based human therapy |
| US5912017A (en) | 1987-05-01 | 1999-06-15 | Massachusetts Institute Of Technology | Multiwall polymeric microspheres |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5268455A (en) | 1989-05-25 | 1993-12-07 | Genentech, Inc. | Process for making biologically active polypeptides based on transforming growth factor-βsequences |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5843452A (en) | 1992-11-09 | 1998-12-01 | Pharmagenesis, Inc. | Immunotherapy composition and method |
| US5679347A (en) | 1992-12-10 | 1997-10-21 | Brigham And Women's Hospital | Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods |
| DE69418699T2 (de) | 1993-01-11 | 1999-09-30 | Dana-Farber Cancer Institute, Boston | Induktion der antworten zytotoxischer t-lymphozyten |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5468729A (en) | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
| WO1995031480A1 (en) | 1994-05-18 | 1995-11-23 | S.P.I. Synthetic Peptides Incorporated | Heterodimer polypeptide immunogen carrier composition and method |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5814617A (en) * | 1994-10-07 | 1998-09-29 | The United States Of America As Represented By The Secretary Of The Navy | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene |
| JPH10507758A (ja) | 1994-10-19 | 1998-07-28 | ジェネティック セラピー，インコーポレイテッド | アデノウイルスおよび免疫抑制剤同時反復投与を伴う遺伝子治療 |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US6251957B1 (en) | 1995-02-24 | 2001-06-26 | Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant virus |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
| EP0889954A1 (en) | 1996-09-03 | 1999-01-13 | Health Research, Inc. | Treatment of antigen presenting cells to modulate antigen presenting cell function |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| AU741130B2 (en) | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| PL187544B1 (pl) | 1997-10-30 | 2004-07-30 | C B F Leti Sa | Wywołujące tolerancję fragmenty naturalnych alergenów |
| US6018817A (en) | 1997-12-03 | 2000-01-25 | International Business Machines Corporation | Error correcting code retrofit method and apparatus for multiple memory configurations |
| US6197229B1 (en) | 1997-12-12 | 2001-03-06 | Massachusetts Institute Of Technology | Method for high supercoiled DNA content microspheres |
| WO1999032647A1 (en) | 1997-12-23 | 1999-07-01 | Introgene B.V. | Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells |
| JP2002500198A (ja) | 1998-01-09 | 2002-01-08 | サーカシア リミテッド | 脱感作のための方法及び組成物 |
| FR2775435B1 (fr) | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| SE9801288D0 (sv) | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| PL202799B1 (pl) | 1998-08-06 | 2009-07-31 | Mountain View Pharmaceuticals | Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza |
| KR100731820B1 (ko) | 1998-10-05 | 2007-06-25 | 파멕사 에이/에스 | 치료적 백신화를 위한 새로운 방법 |
| US6306640B1 (en) | 1998-10-05 | 2001-10-23 | Genzyme Corporation | Melanoma antigenic peptides |
| ATE348163T1 (de) | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| ES2639020T3 (es) | 1998-11-27 | 2017-10-25 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la substancia ósea |
| US6153217A (en) * | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
| US6800296B1 (en) | 1999-05-19 | 2004-10-05 | Massachusetts Institute Of Technology | Modification of surfaces using biological recognition events |
| WO2000074688A1 (en) | 1999-06-08 | 2000-12-14 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
| DE19951970A1 (de) | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
| MXPA02008361A (es) | 2000-02-28 | 2004-05-17 | Genesegues Inc | Sistema y metodo de encapsulacion de nanocapsulas. |
| US20010055593A1 (en) | 2000-03-14 | 2001-12-27 | Joseph Sypek | Use of rapamycin and agents that inhibit B7 activity in immunomodulation |
| EP1278542A2 (en) | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
| WO2001091802A1 (en) | 2000-05-30 | 2001-12-06 | Baylor College Of Medicine | Chimeric viral vectors for gene therapy |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020014242A1 (en) | 2000-07-31 | 2002-02-07 | Abraham Scaria | Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| MY138883A (en) * | 2000-08-29 | 2009-08-28 | Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia | Use of asiatic acid for treatment of cencer |
| CA2319928A1 (en) | 2000-09-18 | 2002-03-18 | Vasogen Ireland Limited | Apoptosis-mimicking synthetic entities and use thereof in medical treatments |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| AU2002338571A1 (en) * | 2001-04-11 | 2002-11-11 | Trustees Of The University Of Pennsylvania | Compositions and methods for suppressing immune responses |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| CN1294268C (zh) | 2001-09-03 | 2007-01-10 | 上海三维生物技术有限公司 | 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体 |
| HRP20070058B1 (hr) | 2001-10-19 | 2014-05-23 | Isotechnika Inc. | Sinteza ciklosporinskih analoga |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| GB0207440D0 (en) | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
| US20040038303A1 (en) | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
| EP1549277A4 (en) | 2002-05-22 | 2007-09-05 | Cleveland Clinic Foundation | INDUCING AND MAINTAINING COMPLEX TISSUE ALLOGRAFT TOLERANCE |
| AU2003237416A1 (en) | 2002-06-04 | 2003-12-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Novel tolerogenic dendritic cells and therapeutic uses therefor |
| SG167667A1 (en) | 2002-07-03 | 2011-01-28 | Coley Pharm Group Inc | Nucleic acid compositions for stimulating immune responses |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| DK1565183T3 (da) | 2002-11-29 | 2008-12-01 | Maria Grazia Roncarolo | Rapamycin og IL-10 til behandling af autoimmune sygdomme |
| US8575110B2 (en) | 2003-02-17 | 2013-11-05 | Alpha-O Peptides G | Peptidic nanoparticles as drug delivery and antigen display systems |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| MXPA05009556A (es) | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
| CN101675993A (zh) | 2003-03-26 | 2010-03-24 | 赛托斯生物技术公司 | Melan-a肽类似物-病毒样颗粒偶联物 |
| US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| CN1835974A (zh) | 2003-06-16 | 2006-09-20 | 细胞技术研究与发展公司 | 对硬化素特异的抗体和用于增加骨矿化的方法 |
| US20060251711A1 (en) | 2003-08-28 | 2006-11-09 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating diseases of the respiratory tract of a mammal |
| US20080160089A1 (en) | 2003-10-14 | 2008-07-03 | Medivas, Llc | Vaccine delivery compositions and methods of use |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| JP2008504216A (ja) | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | モノクローナル抗体の生成のための方法および組成物 |
| WO2005101466A2 (en) | 2003-12-19 | 2005-10-27 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography |
| JP5080241B2 (ja) | 2004-04-08 | 2012-11-21 | メルク セローノ ソシエテ アノニム | Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物 |
| CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| WO2006080951A2 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| WO2006014579A2 (en) | 2004-07-08 | 2006-02-09 | The Regents Of California | Enhancing class i antigen presentation with synthetic sequences |
| FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
| EP1812061A2 (en) | 2004-10-05 | 2007-08-01 | Tanox Inc. | Treatment and prevention of hypersensitivity and/or anaphylaxis with anti-ige antibodies in patients receiving replacement therapy |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| JP2008524239A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
| CA2858733C (en) | 2004-12-31 | 2017-12-19 | Iceutica Pty Ltd | Nanoparticle compositions and methods for synthesis thereof |
| GB0504206D0 (en) | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
| BRPI0608573A2 (pt) | 2005-03-08 | 2017-07-25 | Lifecycle Pharma As | Composição farmacêutica, e, método para a preparação de uma composição farmacêutica. |
| US20060210638A1 (en) * | 2005-03-17 | 2006-09-21 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| WO2006110862A2 (en) | 2005-04-12 | 2006-10-19 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
| JP2008540558A (ja) | 2005-05-10 | 2008-11-20 | エモリー・ユニバーシティ | ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 |
| CA2611985C (en) | 2005-06-17 | 2016-08-16 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| WO2007024026A1 (ja) | 2005-08-25 | 2007-03-01 | Taiho Pharmaceutical Co., Ltd. | Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子 |
| CN1979166A (zh) * | 2005-11-30 | 2007-06-13 | 北京有色金属研究总院 | 一种制备免疫检测用纳米胶体金的工艺方法及其反应装置 |
| WO2007065167A1 (en) | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| US20070128289A1 (en) * | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
| WO2007067683A2 (en) | 2005-12-08 | 2007-06-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for expanding t regulatory cells |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
| DK1984007T3 (en) | 2006-02-13 | 2015-12-07 | Oncolytics Biotech Inc | Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy |
| US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
| US8568487B2 (en) | 2006-02-27 | 2013-10-29 | Biomet Manufacturing, Llc | Patient-specific hip joint devices |
| TW200806789A (en) | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
| EP2012828A2 (en) | 2006-04-28 | 2009-01-14 | Resolvyx Pharmaceuticals, Inc. | Compositions and methods for the treatment of cardiovascular disease |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| WO2007137117A2 (en) | 2006-05-17 | 2007-11-29 | Massachusetts Institute Of Technology | Aptamer-directed drug delivery |
| EP1880729A1 (en) | 2006-07-20 | 2008-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of soluble CD160 to suppress immunity |
| CN104177464B (zh) * | 2006-08-18 | 2017-04-12 | 阿哥斯医疗公司 | Cd83在联合治疗中的用途 |
| US20120269774A1 (en) | 2006-09-21 | 2012-10-25 | Medistem Laboratories, Inc | Allogeneic stem cell transplants in non-conditioned recipients |
| US8313777B2 (en) | 2006-10-05 | 2012-11-20 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
| CN101646418B (zh) | 2006-10-12 | 2013-07-17 | 昆士兰大学 | 调节免疫应答的组合物和方法 |
| CA2702340C (en) | 2006-10-12 | 2014-12-16 | The University Of Queensland | Compositions and methods for modulating immune responses |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008064357A2 (en) | 2006-11-22 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Nanoparticles for protection of cells from oxidative stress |
| WO2008069942A2 (en) | 2006-12-05 | 2008-06-12 | Biogen Idec Ma Inc. | Novel methods of enhancing delivery of a gene therapy vector using steroids |
| WO2008083331A2 (en) | 2006-12-29 | 2008-07-10 | The Regents Of The University Of Colorado | Diagnostic and therapeutic target for autoimmune diseases and uses thereof |
| EP2112930B1 (en) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| KR20080078204A (ko) | 2007-02-22 | 2008-08-27 | 크레아젠 주식회사 | 면역억제능이 증가된 간엽줄기세포-매개 자가유래수지상세포 |
| JP5650406B2 (ja) | 2007-03-07 | 2015-01-07 | ユーティーアイ リミテッド パートナーシップ | 自己免疫状態の予防および治療のための組成物および方法 |
| EP3417859A1 (en) | 2007-03-07 | 2018-12-26 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| EP2061440A2 (en) | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| US20090074828A1 (en) | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
| US20090226525A1 (en) | 2007-04-09 | 2009-09-10 | Chimeros Inc. | Self-assembling nanoparticle drug delivery system |
| JP2010523656A (ja) | 2007-04-12 | 2010-07-15 | エモリー・ユニバーシティ | ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略 |
| WO2008150868A1 (en) | 2007-05-29 | 2008-12-11 | The Board Of Trustees Of The University Of Illinois | Methods for inducing therapeutic t cells for immune diseases |
| US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
| EP2468763B1 (en) | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| AU2008258646A1 (en) | 2007-06-05 | 2008-12-11 | Fondazione Centro San Raffaele Del Monte Tabor | Induction of tolerogenic phenotype in mature dendritic cells |
| US20090004259A1 (en) | 2007-06-14 | 2009-01-01 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) | Methods of preparing a therapeutic formulation comprising galectin-induced tolerogenic dendritic cells |
| WO2009007750A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| BRPI0815395A2 (pt) | 2007-08-15 | 2015-02-10 | Circassia Ltd | Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição. |
| JP2011520769A (ja) * | 2007-09-21 | 2011-07-21 | サイトイミューン サイエンシズ インコーポレイテッド | ナノ治療コロイド金属組成物および方法 |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| WO2009062502A1 (en) | 2007-11-13 | 2009-05-22 | Dandrit Biotech A/S | Method for generating tolerogenic dendritic cells employing decreased temperature |
| US20090142318A1 (en) * | 2007-11-30 | 2009-06-04 | Therakos, Inc. | METHOD TO EXPAND nTREG CELLS USING p70 S6 KINASE ANTAGONIST |
| JP2011512326A (ja) | 2007-12-31 | 2011-04-21 | ナノコア セラピューティクス，インコーポレイテッド | 心不全の治療用のｒｎａ干渉 |
| JP5474831B2 (ja) | 2008-02-08 | 2014-04-16 | テルモ株式会社 | 生理活性物質管腔内制御送達用薬剤送達装置およびその作成方法 |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| CA2722184A1 (en) | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
| AU2009246169B2 (en) | 2008-05-15 | 2015-01-22 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
| JP5549014B2 (ja) | 2008-05-27 | 2014-07-16 | 国立大学法人名古屋大学 | 免疫調節剤及びその利用 |
| US20090297621A1 (en) | 2008-06-03 | 2009-12-03 | Abbott Cardiovascular Systems Inc. | Microparticles For The Treatment Of Disease |
| AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| US20110070154A1 (en) | 2008-08-13 | 2011-03-24 | Hyde Roderick A | Artificial cells |
| US8821887B2 (en) | 2008-08-15 | 2014-09-02 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of IL-10 production |
| US8323696B2 (en) * | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| EP2341953B1 (en) | 2008-09-04 | 2018-11-21 | The General Hospital Corporation | Hydrogels for vocal cord and soft tissue augmentation and repair |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| JP5552630B2 (ja) | 2008-10-24 | 2014-07-16 | 学校法人 聖マリアンナ医科大学 | Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法 |
| WO2010047839A1 (en) | 2008-10-25 | 2010-04-29 | Aura Biosciences | Modified plant virus particles and uses therefor |
| WO2010056143A1 (en) | 2008-11-13 | 2010-05-20 | Instituto De Medicina Molecular | The use of adjuvant to facilitate the induction of immune tolerance |
| EA201100765A1 (ru) | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| MX2011007559A (es) | 2009-01-20 | 2011-12-06 | Myelin Repair Foundation Inc | Composiciones y metodos para induccion de tolerancia antigeno-especifica. |
| EP2218784A1 (en) | 2009-02-04 | 2010-08-18 | Universität Leipzig | Vector(s) containing an inducible gene encoding a CDK4/CD6 inhibitor useful for treating neurodegenerative disorders |
| SI2393830T1 (sl) | 2009-02-05 | 2015-04-30 | Circassia Limited | Travni peptidi za cepivo |
| KR20100099849A (ko) | 2009-03-04 | 2010-09-15 | 동국대학교 산학협력단 | 면역억제제와 트랜스글루타미나제 2의 억제제를 함유한 아토피 피부염 치료용 조성물 |
| US8679837B2 (en) | 2009-04-02 | 2014-03-25 | University Of Florida Research Foundation, Inc. | Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors |
| GB0906159D0 (en) | 2009-04-09 | 2009-05-20 | Summit Corp Plc | Drug combination for the treatment of proteostatic diseases |
| AU2010239689A1 (en) | 2009-04-21 | 2011-11-03 | Selecta Biosciences, Inc. | Immunonanotherapeutics providing a Th1-biased response |
| WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| MX2011011376A (es) | 2009-04-27 | 2012-04-20 | Immuron Ltd | Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| JP2012531596A (ja) | 2009-06-25 | 2012-12-10 | サヴィエント・ファーマシューティカルズ・インコーポレイテッド | Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット |
| CN107617110A (zh) | 2009-08-26 | 2018-01-23 | 西莱克塔生物科技公司 | 诱导t细胞辅助的组合物 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2305277A1 (en) | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
| CN101703781A (zh) * | 2009-10-28 | 2010-05-12 | 陕西北美基因股份有限公司 | 一种免疫抑制剂的磁性载药方法 |
| KR101267813B1 (ko) | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| WO2011085231A2 (en) | 2010-01-08 | 2011-07-14 | Selecta Biosciences, Inc. | Synthetic virus-like particles conjugated to human papillomavirus capsid peptides for use as vaccines |
| US9228171B2 (en) | 2010-02-05 | 2016-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulatory B cells (tBREGS) and their use |
| WO2011109833A2 (en) | 2010-03-05 | 2011-09-09 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
| US20110272836A1 (en) | 2010-04-12 | 2011-11-10 | Selecta Biosciences, Inc. | Eccentric vessels |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| BR112012028557A2 (pt) | 2010-05-07 | 2019-09-24 | Xoma Technology Ltd. | uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo. |
| CN107029223A (zh) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | 合成纳米载体联合疫苗 |
| CA2801891C (en) | 2010-06-07 | 2020-10-27 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| EP2600878A4 (en) | 2010-08-04 | 2014-06-11 | Univ Duke | REGULATORY B-CELLS AND ITS USES |
| AU2011289579B2 (en) | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| WO2012024621A2 (en) | 2010-08-20 | 2012-02-23 | Selecta Biosciences, Inc. | Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin |
| US20120070493A1 (en) | 2010-08-23 | 2012-03-22 | Selecta Biosciences, Inc. | Targeted multi-epitope dosage forms for induction of an immune response to antigens |
| CA2810842C (en) | 2010-09-09 | 2018-06-26 | Micell Technologies, Inc. | Macrolide dosage forms |
| EP2630493A4 (en) | 2010-10-22 | 2014-05-21 | Univ Florida | ANTIGEN-SPECIFIC TOLERANCE-INDUCING MICROPARTICLES AND USES THEREOF |
| EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
| US20120171229A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
| BR112013020273A2 (pt) | 2011-02-08 | 2016-10-18 | Charlotte Mecklenburg Hospital | oligonucleotídeos antissenso |
| ES2685611T3 (es) | 2011-02-14 | 2018-10-10 | The Children's Hospital Of Philadelphia | Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo |
| US8654487B2 (en) | 2011-03-11 | 2014-02-18 | Siemens Industry, Inc. | Methods, systems, and apparatus and for detecting parallel electrical arc faults |
| US20120244222A1 (en) | 2011-03-25 | 2012-09-27 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
| EP3699286A1 (en) | 2011-04-20 | 2020-08-26 | The Trustees of the University of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| AU2012256281B2 (en) | 2011-05-16 | 2017-06-15 | Genzyme Corporation | Induction of immune tolerance by using methotrexate |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| WO2013036296A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Compositions and methods for producing antigen-specific induced tolerogenic dendritic cells with synthetic nanocarriers |
| EP2753362A4 (en) | 2011-09-08 | 2015-04-15 | Univ Florida | MATERIALS AND METHOD FOR MODULATING IMMUNE SYSTEM REACTIONS |
| US8865487B2 (en) | 2011-09-20 | 2014-10-21 | General Electric Company | Large area hermetic encapsulation of an optoelectronic device using vacuum lamination |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| WO2013058812A1 (en) | 2011-10-19 | 2013-04-25 | President And Fellows Of Harvard College | Targeted delivery to pancreatic islet endothelial cells |
| EP2591801A1 (en) | 2011-11-14 | 2013-05-15 | Universitätsklinikum Hamburg-Eppendorf | Nanoparticle compositions for generation of regulatory T cells and treatment of autoimmune diseases and other chronic inflammatory conditions |
| EP2782596A4 (en) | 2011-11-22 | 2015-07-29 | Philadelphia Children Hospital | VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENIC ADMINISTRATION |
| BR112014020325A2 (pt) | 2012-02-17 | 2017-08-08 | Childrens Hospital Philadelphia | composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos |
| JP6342886B2 (ja) | 2012-04-18 | 2018-06-13 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法 |
| CN109876139A (zh) | 2012-04-24 | 2019-06-14 | 俄亥俄州国家创新基金会 | 用于治疗和预防猪繁殖与呼吸综合征的组合物和方法 |
| BR112015005878A2 (pt) | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas |
| CN102871966B (zh) | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
| US9944918B2 (en) | 2013-03-15 | 2018-04-17 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Synthetic methylmalonyl-CoA mutase transgene for the treatment of MUT class methylmalonic acidemia (MMA) |
| US20160038575A1 (en) | 2013-03-15 | 2016-02-11 | Haplomics, Inc. | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a |
| AU2014251099B2 (en) | 2013-04-08 | 2019-01-17 | The University Of Kansas | Chimeric adeno-associated virus/ bocavirus parvovirus vector |
| TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| WO2014179771A1 (en) | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| ES2834129T3 (es) | 2013-06-04 | 2021-06-16 | Selecta Biosciences Inc | Administración repetida de agentes inmunoterapéuticos específicos de antígeno no inmunosupresores |
| CA2926215A1 (en) | 2013-10-06 | 2015-04-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modified pseudomonas exotoxin a |
| US9276815B2 (en) * | 2013-12-27 | 2016-03-01 | Dell Products L.P. | N-node virtual link trunking (VLT) systems management plane |
| EP2916319A1 (en) | 2014-03-07 | 2015-09-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Concept for encoding of information |
| BR112016020688B1 (pt) | 2014-03-09 | 2024-01-30 | The Trustees Of The University Of Pennsylvania | Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos |
| GB201407322D0 (en) | 2014-04-25 | 2014-06-11 | Ospedale San Raffaele | Gene therapy |
| US20150358333A1 (en) * | 2014-06-04 | 2015-12-10 | Grandios Technologies, Llc | Geo-location and biometric presence security |
| US20150359865A1 (en) | 2014-06-17 | 2015-12-17 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for t-cell-mediated autoimmune disease |
| US20160220501A1 (en) | 2015-02-03 | 2016-08-04 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
| EP3160453A1 (en) | 2014-06-25 | 2017-05-03 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| CN107002096A (zh) | 2014-10-06 | 2017-08-01 | 阿罗根有限公司 | 基于aav的基因疗法 |
| AU2015342968B2 (en) | 2014-11-05 | 2021-05-27 | Selecta Biosciences, Inc. | Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog |
| TWI726897B (zh) | 2015-07-15 | 2021-05-11 | 日商協和麒麟股份有限公司 | 與人類ｃｒｔｈ２特異性結合之抗體 |
| WO2017139212A1 (en) | 2016-02-08 | 2017-08-17 | Cyta Therapeutics, Inc. | Particle delivery of rapamycin to the liver |
| AU2016392719A1 (en) | 2016-02-10 | 2018-08-02 | Pfizer Inc. | Therapeutic nanoparticles having EGFR ligands and methods of making and using same |
| RS65941B1 (sr) | 2016-03-11 | 2024-10-31 | Cartesian Therapeutics Inc | Formulacije i doze pegilovane urikaze |
| GB201608323D0 (en) | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| US10545815B2 (en) | 2016-08-03 | 2020-01-28 | Futurewei Technologies, Inc. | System and method for data redistribution in a database |
| US20180071394A1 (en) | 2016-08-25 | 2018-03-15 | Selecta Biosciences, Inc. | Polyester polymer matrices for the delivery of allergens |
| CN109922819A (zh) | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | 用于治疗癌症的重组免疫毒素 |
| EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018093868A1 (en) | 2016-11-16 | 2018-05-24 | University Of Florida Research Foundation, Inc. | Immunoglobulin proteases, compositions, and uses thereof |
| US11104887B2 (en) | 2017-01-03 | 2021-08-31 | Ethris Gmbh | Ornithine transcarbamylase coding polyribonucleotides and formulations thereof |
| JP2020506890A (ja) | 2017-01-07 | 2020-03-05 | セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与 |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| KR102717886B1 (ko) | 2018-02-26 | 2024-10-16 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 약물 전달 시스템 |
| AU2019265632A1 (en) | 2018-05-09 | 2021-01-07 | Yale University | Particles for spatiotemporal release of agents |
| CN112771070A (zh) | 2018-07-16 | 2021-05-07 | 西莱克塔生物科技公司 | Otc构建体和载体的方法和组合物 |
| EP3823676A1 (en) | 2018-07-16 | 2021-05-26 | Selecta Biosciences, Inc. | Methods and compositions of mma constructs and vectors |
| CA3138525A1 (en) | 2019-04-28 | 2020-11-05 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| US20210154324A1 (en) | 2019-10-21 | 2021-05-27 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| IL292770A (en) | 2019-11-08 | 2022-07-01 | Selecta Biosciences Inc | Formulations and dosages of polyethylene glycol-modified oricase |
| MX2022010568A (es) | 2020-02-26 | 2022-11-30 | Selecta Biosciences Inc | Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor. |
| CA3174988A1 (en) | 2020-03-11 | 2021-09-16 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| CN120078887A (zh) | 2020-09-21 | 2025-06-03 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| MX2023005224A (es) | 2020-11-04 | 2023-07-18 | Selecta Biosciences Inc | Composiciones para reducir las respuestas inmunes contra inmunoglobulina proteasas. |
| AU2022206197A1 (en) | 2021-01-05 | 2023-07-13 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR20230167405A (ko) | 2021-04-09 | 2023-12-08 | 셀렉타 바이오사이언시즈, 인크. | 면역 관용을 증진시키기 위해 고친화도 il-2 수용체 효능제와 조합된 면역억제제를 포함하는 합성 나노담체 |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| US20230140196A1 (en) | 2021-10-12 | 2023-05-04 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| US20230141563A1 (en) | 2021-10-12 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| US20230357437A1 (en) | 2022-03-09 | 2023-11-09 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| JP2025526816A (ja) | 2022-08-11 | 2025-08-15 | カーティザン セラピューティクス，インコーポレーテッド | 免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法 |
-
2014
- 2014-05-02 CN CN201480031937.3A patent/CN105307641A/zh active Pending
- 2014-05-02 CA CA2910575A patent/CA2910575C/en active Active
- 2014-05-02 US US14/269,048 patent/US10668053B2/en active Active
- 2014-05-02 JP JP2016512094A patent/JP6580558B2/ja active Active
- 2014-05-02 EP EP14791496.4A patent/EP2991646B1/en active Active
- 2014-05-02 KR KR1020157034143A patent/KR20160003219A/ko not_active Ceased
- 2014-05-02 KR KR1020227004758A patent/KR20220025907A/ko not_active Ceased
- 2014-05-02 MX MX2015015230A patent/MX386917B/es unknown
- 2014-05-02 KR KR1020247024664A patent/KR20240119156A/ko not_active Ceased
- 2014-05-02 KR KR1020157034133A patent/KR20160003217A/ko not_active Ceased
- 2014-05-02 US US14/269,058 patent/US10335395B2/en active Active
- 2014-05-02 BR BR112015027297-5A patent/BR112015027297B1/pt active IP Right Grant
- 2014-05-02 BR BR112015027281-9A patent/BR112015027281B1/pt active IP Right Grant
- 2014-05-02 EA EA201592104A patent/EA201592104A3/ru unknown
- 2014-05-02 KR KR1020157034104A patent/KR20160003830A/ko not_active Ceased
- 2014-05-02 CN CN201910874364.5A patent/CN110694077A/zh active Pending
- 2014-05-02 CN CN201911307714.6A patent/CN111053908A/zh active Pending
- 2014-05-02 KR KR1020157034102A patent/KR20160003212A/ko not_active Ceased
- 2014-05-02 CN CN201911069542.3A patent/CN110841067A/zh active Pending
- 2014-05-02 CN CN202410981673.3A patent/CN118987263A/zh active Pending
- 2014-05-02 KR KR1020227004756A patent/KR20220025906A/ko not_active Ceased
- 2014-05-02 CN CN201911069459.6A patent/CN110841066A/zh active Pending
- 2014-05-02 CN CN201480037123.0A patent/CN105339012A/zh active Pending
- 2014-05-02 CN CN201910552053.7A patent/CN110251675A/zh active Pending
- 2014-05-02 CN CN201910552107.XA patent/CN110251676A/zh active Pending
- 2014-05-02 EP EP14792080.5A patent/EP2991631A4/en active Pending
- 2014-05-02 CA CA2910578A patent/CA2910578C/en active Active
- 2014-05-02 CA CA2910584A patent/CA2910584A1/en active Pending
- 2014-05-02 KR KR1020227004761A patent/KR20220025910A/ko not_active Ceased
- 2014-05-02 JP JP2016512093A patent/JP6818549B2/ja active Active
- 2014-05-02 HU HUE14791496A patent/HUE052599T2/hu unknown
- 2014-05-02 CN CN201480034670.3A patent/CN105338968A/zh active Pending
- 2014-05-02 BR BR112015027291A patent/BR112015027291A8/pt not_active Application Discontinuation
- 2014-05-02 KR KR1020227004760A patent/KR20220025909A/ko not_active Ceased
- 2014-05-02 IL IL292190A patent/IL292190A/en unknown
- 2014-05-02 EP EP14791089.7A patent/EP2991628A4/en active Pending
- 2014-05-02 KR KR1020247024767A patent/KR20240116963A/ko not_active Ceased
- 2014-05-02 AU AU2014262166A patent/AU2014262166B2/en active Active
- 2014-05-02 CA CA2910417A patent/CA2910417C/en active Active
- 2014-05-02 AU AU2014262155A patent/AU2014262155A1/en not_active Abandoned
- 2014-05-02 DK DK14791496.4T patent/DK2991646T3/da active
- 2014-05-02 KR KR1020227004759A patent/KR20220025908A/ko not_active Ceased
- 2014-05-02 WO PCT/US2014/036699 patent/WO2014179772A2/en not_active Ceased
- 2014-05-02 US US14/269,056 patent/US10357483B2/en active Active
- 2014-05-02 US US14/269,042 patent/US20140335186A1/en active Pending
- 2014-05-02 WO PCT/US2014/036687 patent/WO2014179762A1/en not_active Ceased
- 2014-05-02 CN CN201480032251.6A patent/CN105283175A/zh active Pending
- 2014-05-02 JP JP2016512086A patent/JP2016517889A/ja active Pending
- 2014-05-02 MX MX2015015221A patent/MX394497B/es unknown
- 2014-05-02 AU AU2014262162A patent/AU2014262162B2/en active Active
- 2014-05-02 IL IL284732A patent/IL284732B2/en unknown
- 2014-05-02 CN CN201480037076.XA patent/CN105338979A/zh active Pending
- 2014-05-02 JP JP2016512092A patent/JP6760838B2/ja active Active
- 2014-05-02 EA EA201592106A patent/EA201592106A3/ru unknown
- 2014-05-02 BR BR112015027288-6A patent/BR112015027288B1/pt active IP Right Grant
- 2014-05-02 MX MX2021005697A patent/MX2021005697A/es unknown
- 2014-05-02 EA EA201592107A patent/EA201592107A1/ru unknown
- 2014-05-02 EP EP20167362.1A patent/EP3763359A1/en not_active Withdrawn
- 2014-05-02 IL IL284924A patent/IL284924B2/en unknown
- 2014-05-02 BR BR122020023215-3A patent/BR122020023215B1/pt active IP Right Grant
- 2014-05-02 EP EP14791147.3A patent/EP2991685A4/en not_active Withdrawn
- 2014-05-02 MX MX2015015229A patent/MX2015015229A/es unknown
- 2014-05-02 ES ES14791496T patent/ES2842206T3/es active Active
- 2014-05-02 JP JP2016512091A patent/JP7028556B2/ja active Active
- 2014-05-02 BR BR112015027279A patent/BR112015027279A8/pt not_active Application Discontinuation
- 2014-05-02 KR KR1020247024766A patent/KR20240119161A/ko not_active Ceased
- 2014-05-02 JP JP2016512090A patent/JP2016520051A/ja active Pending
- 2014-05-02 EP EP14791567.2A patent/EP2991630A4/en active Pending
- 2014-05-02 EA EA201592105A patent/EA201592105A1/ru unknown
- 2014-05-02 US US14/269,047 patent/US10434088B2/en active Active
- 2014-05-02 AU AU2014262165A patent/AU2014262165B2/en active Active
- 2014-05-02 CN CN202010594335.6A patent/CN111760025A/zh active Pending
- 2014-05-02 KR KR1020247024665A patent/KR20240119157A/ko not_active Ceased
- 2014-05-02 KR KR1020247024661A patent/KR20240119155A/ko not_active Ceased
- 2014-05-02 CN CN201910874452.5A patent/CN110639024A/zh active Pending
- 2014-05-02 US US14/269,054 patent/US10357482B2/en active Active
- 2014-05-02 WO PCT/US2014/036696 patent/WO2014179769A2/en not_active Ceased
- 2014-05-02 CN CN202410347642.2A patent/CN118370823A/zh active Pending
- 2014-05-02 EA EA201592103A patent/EA201592103A3/ru unknown
- 2014-05-02 WO PCT/US2014/036700 patent/WO2014179773A2/en not_active Ceased
- 2014-05-02 KR KR1020247024763A patent/KR20240119160A/ko not_active Ceased
- 2014-05-02 MX MX2015015231A patent/MX2015015231A/es unknown
- 2014-05-02 MX MX2015015223A patent/MX380164B/es unknown
- 2014-05-02 AU AU2014262163A patent/AU2014262163A1/en not_active Abandoned
- 2014-05-02 CN CN202010594054.0A patent/CN111686255A/zh active Pending
- 2014-05-02 EA EA201592102A patent/EA201592102A1/ru unknown
- 2014-05-02 KR KR1020157034121A patent/KR20160003215A/ko not_active Ceased
- 2014-05-02 EP EP14791119.2A patent/EP2991629A4/en active Pending
- 2014-05-02 KR KR1020227004763A patent/KR20220025911A/ko not_active Ceased
- 2014-05-02 KR KR1020157034120A patent/KR20160003214A/ko not_active Ceased
- 2014-05-02 CN CN201480032224.9A patent/CN105263478A/zh active Pending
- 2014-05-02 WO PCT/US2014/036697 patent/WO2014179770A1/en not_active Ceased
- 2014-05-02 CN CN201911306104.4A patent/CN111068061A/zh active Pending
- 2014-05-02 CA CA2910583A patent/CA2910583C/en active Active
- 2014-05-02 MX MX2015015225A patent/MX382604B/es unknown
-
2015
- 2015-10-22 IL IL24221615A patent/IL242216B/en active IP Right Grant
- 2015-10-26 IL IL242271A patent/IL242271B/en active IP Right Grant
- 2015-10-26 IL IL24227015A patent/IL242270B/en active IP Right Grant
- 2015-10-26 IL IL242273A patent/IL242273B/en active IP Right Grant
- 2015-10-26 IL IL242272A patent/IL242272B/en active IP Right Grant
- 2015-10-30 MX MX2021001878A patent/MX2021001878A/es unknown
- 2015-10-30 MX MX2022009538A patent/MX2022009538A/es unknown
- 2015-10-30 MX MX2021001879A patent/MX2021001879A/es unknown
- 2015-10-30 MX MX2021001982A patent/MX2021001982A/es unknown
- 2015-10-30 MX MX2021012348A patent/MX2021012348A/es unknown
-
2018
- 2018-12-10 JP JP2018231206A patent/JP6983144B2/ja active Active
-
2019
- 2019-01-15 JP JP2019004287A patent/JP7134885B2/ja active Active
- 2019-05-13 US US16/410,876 patent/US20200069659A1/en not_active Abandoned
- 2019-06-06 US US16/433,622 patent/US20200069660A1/en not_active Abandoned
- 2019-06-11 US US16/438,147 patent/US11298342B2/en active Active
- 2019-08-26 US US16/550,725 patent/US20200113874A1/en not_active Abandoned
- 2019-08-28 JP JP2019155456A patent/JP2020015741A/ja active Pending
- 2019-10-15 AU AU2019250117A patent/AU2019250117B2/en active Active
- 2019-10-24 IL IL270133A patent/IL270133B/en unknown
- 2019-10-24 IL IL270135A patent/IL270135B/en unknown
- 2019-10-28 JP JP2019195263A patent/JP7427419B2/ja active Active
- 2019-12-02 JP JP2019217946A patent/JP2020073488A/ja active Pending
-
2020
- 2020-01-04 AU AU2020200065A patent/AU2020200065B2/en active Active
- 2020-01-24 AU AU2020200565A patent/AU2020200565A1/en not_active Abandoned
- 2020-02-05 AU AU2020200824A patent/AU2020200824A1/en not_active Abandoned
- 2020-04-24 US US16/858,349 patent/US12508249B2/en active Active
- 2020-05-21 AU AU2020203308A patent/AU2020203308A1/en not_active Abandoned
- 2020-05-21 IL IL274852A patent/IL274852B/en unknown
- 2020-07-21 IL IL276205A patent/IL276205B/en active IP Right Grant
-
2021
- 2021-01-04 JP JP2021000191A patent/JP2021073198A/ja active Pending
- 2021-03-24 US US17/211,459 patent/US20220071968A1/en not_active Abandoned
- 2021-04-04 IL IL282045A patent/IL282045B/en unknown
- 2021-09-30 JP JP2021162235A patent/JP7489362B2/ja active Active
- 2021-11-29 JP JP2021193530A patent/JP2022043071A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200157A patent/AU2022200157A1/en not_active Abandoned
- 2022-03-09 AU AU2022201641A patent/AU2022201641B2/en active Active
- 2022-03-09 US US17/690,437 patent/US12472167B2/en active Active
- 2022-03-15 IL IL291394A patent/IL291394A/en unknown
- 2022-05-06 JP JP2022076702A patent/JP2022122871A/ja active Pending
- 2022-05-06 JP JP2022076787A patent/JP7440833B2/ja active Active
- 2022-05-11 AU AU2022203142A patent/AU2022203142B2/en active Active
- 2022-05-25 AU AU2022203540A patent/AU2022203540A1/en not_active Abandoned
- 2022-12-09 JP JP2022197386A patent/JP7864061B2/ja active Active
-
2023
- 2023-05-11 AU AU2023202955A patent/AU2023202955A1/en not_active Abandoned
- 2023-12-01 US US18/527,060 patent/US20240350462A1/en active Pending
-
2024
- 2024-05-13 JP JP2024077998A patent/JP2024116128A/ja active Pending
- 2024-06-28 US US18/757,781 patent/US20250177360A1/en active Pending
- 2024-08-21 AU AU2024213104A patent/AU2024213104A1/en not_active Abandoned
- 2024-09-13 JP JP2024159048A patent/JP2025003994A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019069964A5 (enExample) | ||
| JP2022025069A5 (enExample) | ||
| JP2020045343A5 (enExample) | ||
| JP2016517890A5 (enExample) | ||
| JP2022043071A5 (enExample) | ||
| JP2019089784A5 (enExample) | ||
| JP2016517891A5 (enExample) | ||
| JP2016520051A5 (enExample) | ||
| JP2022115998A5 (enExample) | ||
| JP2017114904A5 (enExample) | ||
| JP2021183613A5 (enExample) | ||
| JP2014513102A5 (enExample) | ||
| JP2020015741A5 (enExample) | ||
| JP2016518392A5 (enExample) | ||
| Pipe et al. | Hemophilia A gene therapy: current and next-generation approaches | |
| CN100352500C (zh) | 稳定的抗体液体制剂 | |
| JP2019089784A (ja) | 非アレルゲン性の抗原に応答するアナフィラキシーを低減または防止するための寛容原性合成ナノ担体 | |
| AU2008214359B2 (en) | Local complement inhibition for treatment of complement-mediated disorders | |
| CN108210889A (zh) | 通过施用重组vwf治疗凝血疾病 | |
| JP2025526816A (ja) | 免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法 | |
| Mukovozov et al. | Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins | |
| Shetty et al. | Novel therapeutic approaches for haemophilia | |
| Pipe | Hemophilia: new protein therapeutics | |
| Meibohm | Pharmacokinetics and pharmacodynamics of therapeutic peptides and proteins | |
| Gernsheimer | The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura |